Search hospitals > Arkansas > Little Rock
Arkansas Children's Hospital
Claim this profileLittle Rock, Arkansas 72202
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoma
Conducts research for Neuroblastoma
Conducts research for Recurrence
450 reported clinical trials
24 medical researchers
Summary
Arkansas Children's Hospital is a medical facility located in Little Rock, Arkansas. This center is recognized for care of Leukemia, Tumors, Lymphoma, Neuroblastoma, Recurrence and other specialties. Arkansas Children's Hospital is involved with conducting 450 clinical trials across 681 conditions. There are 24 research doctors associated with this hospital, such as David L. Becton, Aravindhan Veerapandiyan, Kevin Bielamowicz, MD, and Stacie Jones, MD.Area of expertise
1Leukemia
Global LeaderStage II
Philadelphia chromosome positive
BCR-ABL1 positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
David L. BectonArkansas Children's Hospital7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
66 reported clinical trials
113 drugs studied
Aravindhan VeerapandiyanArkansas Children's Hospital1 year of reported clinical research
Studies Muscular Dystrophy
Studies Duchenne Muscular Dystrophy
13 reported clinical trials
10 drugs studied
Kevin Bielamowicz, MDArkansas Children's Hospital4 years of reported clinical research
Studies Neuroblastoma
Studies Leukemia
12 reported clinical trials
23 drugs studied
Stacie Jones, MDArkansas Children's Hospital5 years of reported clinical research
Studies Allergy
Studies Food Allergy
5 reported clinical trials
8 drugs studied
Clinical Trials running at Arkansas Children's Hospital
Acute Myeloid Leukemia
Langerhans Cell Histiocytosis
Osteosarcoma
Acute Lymphoblastic Leukemia
Acute Leukemia
Brain Tumor
Germ Cell Tumors
Leukemia
Neuroblastoma
Astrocytoma
Stem Cell Transplantation
for Leukemia
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
Recruiting2 awards Phase 3
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
Recruiting2 awards Phase 34 criteria
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Arkansas Children's Hospital?
Arkansas Children's Hospital is a medical facility located in Little Rock, Arkansas. This center is recognized for care of Leukemia, Tumors, Lymphoma, Neuroblastoma, Recurrence and other specialties. Arkansas Children's Hospital is involved with conducting 450 clinical trials across 681 conditions. There are 24 research doctors associated with this hospital, such as David L. Becton, Aravindhan Veerapandiyan, Kevin Bielamowicz, MD, and Stacie Jones, MD.
Where is Arkansas Children's Hospital located?
**Arkansas Children's Hospital Location:**
- **Address:** 1 Children's Way, Little Rock, AR 72202.
- **Directions:** From I-630, take Exit 2B to Dr. Martin Luther King Jr. Blvd, then turn onto Children's Way.
Who should I call to ask about financial aid or insurance network?
**Arkansas Children's Hospital Financial and Insurance Information:**
- **Financial Assistance:** For inquiries, contact the Admissions Office at 501-364-1230 or toll-free at 1-800-280-1230.
- **Insurance and Managed Care Inquiries:** Reach an English or Spanish-speaking counselor at 501-364-1230.
- The hospital accepts a variety of insurance plans and provides financial assistance programs for eligible patients.
What insurance does Arkansas Children's Hospital accept?
Arkansas Children's Hospital accepts a wide range of insurance plans, including but not limited to AETNA, American LifeCare, AR BCBS – Arkansas First Source, Cigna, Coventry Health Care, Humana, Medicaid, Medicare, Tricare, and United Healthcare. They offer both a Preferred Provider Option (PPO) and a High Deductible Health Plan (HDHP) through BlueAdvantage Administrators of Arkansas. For specific details regarding coverage and restrictions, contacting the hospital directly or consulting with your insurance company is recommended.
What awards or recognition has Arkansas Children's Hospital received?
Arkansas Children's Research Institute (ACRI) secures over $21 million annually in grants and contracts, underscoring its commitment to academic integrity and effective conflict of interest management. Arkansas Children's Hospital boasts prestigious accolades such as the Gold-Level Beacon Award for Excellence, Magnet status, and Gold Certified Safe Sleep Champion recognition. These awards highlight the hospital's dedication to critical care excellence, nursing excellence, and infant safety.